Intravenous urokinase in acute myocardial infarction
- PMID: 3984876
- DOI: 10.1016/0002-9149(85)90710-6
Intravenous urokinase in acute myocardial infarction
Abstract
To achieve reperfusion early, an intravenous bolus of 2 million units of urokinase was administered in 50 patients with transmural acute myocardial infarction (AMI) 1.8 +/- 2.5 hours after the onset of symptoms. Coronary angiography performed 1.1 +/- 0.6 hours after urokinase therapy revealed patent coronary arteries in 30 patients (60%), with no significant difference between those with anterior and those with inferior AMI. Reocclusion occurred in only 1 of 24 patients restudied. Failure to achieve reperfusion was not related to the degree of systemic fibrinolytic activity, which was equally high in patients who did and those who did not achieve reperfusion, as evident from serially obtained fibrinogen measurements (77 +/- 52 vs 84 +/- 24 mg/dl, difference not significant). Plasmin activity, measured serially from 15 minutes to 24 hours after urokinase in 7 patients, was maximal at 15 minutes and undetectable after 3 hours. Wall motion at the infarct site measured from contrast ventriculograms was significantly better at follow-up only in patients in whom reperfusion was achieved and who received urokinase within 2 hours after the onset of symptoms as compared with patients in whom reperfusion was not achieved (-1.2 +/- 1.4 vs -2.4 +/- 0.9 standard deviations from normal, p less than 0.05). Peak serum creatine kinase level was significantly lower in patients in whom reperfusion was achieved than in those in whom it was not or those who had rethrombosis (802 +/- 763 vs 1,973 +/- 1,071 U/liter, p less than 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Results of high dose intravenous urokinase for acute myocardial infarction.Am J Cardiol. 1990 Jan 15;65(3):124-31. doi: 10.1016/0002-9149(90)90072-9. Am J Cardiol. 1990. PMID: 2296881
-
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.J Am Coll Cardiol. 1986 Jul;8(1):118-24. doi: 10.1016/s0735-1097(86)80101-2. J Am Coll Cardiol. 1986. PMID: 3086416
-
Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.Am J Cardiol. 1988 May 1;61(13):966-70. doi: 10.1016/0002-9149(88)90107-5. Am J Cardiol. 1988. PMID: 2452563 Review.
-
Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).J Am Coll Cardiol. 1988 Sep;12(3):581-7. doi: 10.1016/s0735-1097(88)80040-8. J Am Coll Cardiol. 1988. PMID: 3042835 Clinical Trial.
-
[New thrombolytic agents in myocardial infarction].Arch Mal Coeur Vaiss. 1987 Nov;80(12):1785-91. Arch Mal Coeur Vaiss. 1987. PMID: 3128222 Review. French.
Cited by
-
Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.Tex Heart Inst J. 1991;18(2):103-9. Tex Heart Inst J. 1991. PMID: 15227491 Free PMC article.
-
Use of thrombolytic drugs in non-coronary disorders.Drugs. 1989 Nov;38(5):801-21. doi: 10.2165/00003495-198938050-00006. Drugs. 1989. PMID: 2689138 Review.
-
Guidelines for general practitioners administering thrombolytics.Drugs. 1995 Oct;50(4):615-25. doi: 10.2165/00003495-199550040-00004. Drugs. 1995. PMID: 8536550 Review.
-
Indications for coronary angioplasty in acute myocardial ischemic syndromes.Cardiovasc Drugs Ther. 1988 May;2(1):93-101. doi: 10.1007/BF00054258. Cardiovasc Drugs Ther. 1988. PMID: 3154701 Review.
-
Thrombolytic therapy in acute myocardial infarction.Drugs Aging. 2000 Apr;16(4):301-12. doi: 10.2165/00002512-200016040-00006. Drugs Aging. 2000. PMID: 10874525 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical